
Regimen Monograph

 Regimen Name
 Drug Regimen
 Cycle Frequency
 Premedication and Supportive Measures
 Administrative Information

 References
 Other Notes
 Disclaimer

A - Regimen Name



back to top

Any use of the information is subject, at all times, to CCO's Terms and Conditions.

CISPETOP

B - Drug Regimen

Standard schedule:

<u>CISplatin</u>	80 mg /m²	IV	Day 1
<u>etoposide</u>	100 mg /m²	IV	Days 1 to 3
Alternative Schedule:			
<u>CISplatin</u>	60 mg /m²	IV	Day 1
<u>etoposide</u>	100 to 120 mg /m ²	IV	Days 1 to 3
a alv ta tan			

back to top

C - Cycle Frequency

Standard schedule: REPEAT EVERY 21 to 28 DAYS

Alternative schedule: REPEAT EVERY 21 DAYS

For a usual total of 4 to 6 cycles unless disease progression or unacceptable toxicity occurs

back to top

D - Premedication and Supportive Measures

Antiemetic Regimen: High

Other Supportive Care:

Alternative schedule may have different emetic risk. Also refer to <u>CCO Antiemetic</u> <u>Recommendations</u>.

Standard regimens for Cisplatin premedication and hydration should be followed. Refer to local guidelines.

back to top

Any use of the information is subject, at all times, to CCO's Terms and Conditions.

J - Administrative Information

Approximate Patient Visit	Day 1: 4 hours; Etoposide days: 1 hour
Pharmacy Workload (average time per visit)	18.404 minutes
Nursing Workload (average time per visit)	42.5 minutes

back to top

K - References

Ardizzoni A, Grossi F. Update on the treatment of small cell lung cancer (SCLC). Ann Oncol 2000;11 Suppl 3:101-8.

Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24(13):2038-43.

Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med;346(2):85-91.

Oh IJ, Kim KS, Park CK, et al. Belotecan/cisplatin versus etoposide/cisplatin in previously untreated patients with extensive-stage small cell lung carcinoma: a multi-center randomized phase III trial. BMC Cancer 2016;16:690.

Seckl MJ, Ottensmeier CH, Cullen M, et al. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). J Clin Oncol 2017;35(14):1506-14.

Sun Y, Cheng Y, Hao X, et al. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer. 2016;16:265.

PEBC Advice Documents or Guidelines

- Initial Management of Small Cell Lung Cancer (Limited and Extensive Stage) and the Role of Thoracic Radiotherapy and First-Line Chemotherapy
- Systemic Therapy for Small-Cell Lung Cancer: ASCO-OH(CCO) Guideline

November 2023 Added PEBC guideline link

back to top

Any use of the information is subject, at all times, to CCO's Terms and Conditions.

M - Disclaimer

Regimen Abstracts

A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for the use of this information, and for any claims, actions, demands or suits that arise from such use.

Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Regimen Monographs

Refer to the <u>New Drug Funding Program</u> or <u>Ontario Public Drug Programs</u> websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary's content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.

back to top

Any use of the information is subject, at all times, to CCO's Terms and Conditions.